Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All colchicine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchColchicineColchicine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational study

Manenti et al., PLOS ONE, doi:10.1371/journal.pone.0248276
Mar 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 76% Improvement Relative Risk Recovery 44% Colchicine  Manenti et al.  LATE TREATMENT Is late treatment with colchicine beneficial for COVID-19? Retrospective 141 patients in Italy (March - April 2020) Lower mortality with colchicine (p=0.0054) c19early.org Manenti et al., PLOS ONE, March 2021 Favorscolchicine Favorscontrol 0 0.5 1 1.5 2+
Colchicine for COVID-19
5th treatment shown to reduce risk in September 2020
 
*, now with p = 0.00000031 from 56 studies.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 77 treatments. c19early.org
IPTW retrospective 141 COVID-19 patients (83% hospitalized), 71 treated with colchicine and 70 matched control patients, showing lower mortality and faster recovery with treatment.
risk of death, 76.0% lower, HR 0.24, p = 0.005, treatment 71, control 70, adjusted per study, propensity score weighting.
risk of no recovery, 44.4% lower, RR 0.56, p = 0.048, treatment 71, control 70, adjusted per study, inverted to make RR<1 favor treatment, propensity score weighting.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Manenti et al., 24 Mar 2021, retrospective, Italy, peer-reviewed, 24 authors, study period 1 March, 2020 - 10 April, 2020, dosage 1mg days 1-21.
This PaperColchicineAll
Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational study
Lucio Manenti, Umberto Maggiore, Enrico Fiaccadori, Tiziana Meschi, Anna Degli Antoni, Antonio Nouvenne, Andrea Ticinesi, Nicoletta Cerundolo, Beatrice Prati, Marco Delsante, Ilaria Gandoflini, Lorenzo Donghi, Micaela Gentile, Maria Teresa Farina, Vincenzo Oliva, Cristina Zambrano, Giuseppe Regolisti, Alessandra Palmisano, Caterina Caminiti, Enrico Cocchi, Carlo Ferrari, Leonardo V Riella, Paolo Cravedi, Licia Peruzzi
PLOS ONE, doi:10.1371/journal.pone.0248276
Objectives Effective treatments for coronavirus disease 2019 (COVID-19) are urgently needed. We hypothesized that colchicine, by counteracting proinflammatory pathways implicated in the uncontrolled inflammatory response of COVID-19 patients, reduces pulmonary complications, and improves survival. Methods This retrospective study included 71 consecutive COVID-19 patients (hospitalized with pneumonia on CT scan or outpatients) who received colchicine and compared with 70 control patients who did not receive colchicine in two serial time periods at the same institution. We used inverse probability of treatment propensity-score weighting to examine differences in mortality, clinical improvement (using a 7-point ordinary scale), and inflammatory markers between the two groups. Results Amongst the 141 hospitalized), 70 (50%) received colchicine. The 21-day crude cumulative mortality was 7.5% in the colchicine group and 28.5% in the control group (P = 0.006; adjusted hazard ratio: 0.24 [95%CI: 0.09 to 0.67]); 21-day
Supporting information S1 Table. Demographic and clinical characteristics of the study population after propen Author Contributions Conceptualization: Lucio Manenti, Umberto Maggiore, Paolo Cravedi, Licia Peruzzi. Data curation: Lucio Manenti. Formal analysis: Lucio Manenti. Writing -original draft: Lucio Manenti, Umberto Maggiore, Paolo Cravedi. Writing -review & editing: Umberto Maggiore, Enrico Fiaccadori, Tiziana Meschi, Anna Degli Antoni, Antonio Nouvenne, Andrea Ticinesi, Nicoletta Cerundolo, Beatrice Prati, Marco Delsante, Ilaria Gandoflini, Lorenzo Donghi, Micaela Gentile, Maria Teresa Farina, Vincenzo Oliva, Cristina Zambrano, Giuseppe Regolisti, Alessandra Palmisano, Caterina Caminiti, Enrico Cocchi, Carlo Ferrari, Leonardo V. Riella, Paolo Cravedi, Licia Peruzzi.
References
Ali, Baloch, Ahmed, Ali, Iqbal, The outbreak of Coronavirus Disease 2019 (COVID-19)-An emerging global health threat, J Infect Public Health, doi:10.1016/j.jiph.2020.02.033
Cao, Wang, Wen, Liu, Wang et al., A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19, N Engl J Med, doi:10.1056/NEJMoa2001282
Castaño-Rodriguez, Honrubia, ´rrez-A ´lvarez, Dediego, Nieto-Torres et al., Role of Severe Acute Respiratory Syndrome Coronavirus Viroporins E, 3a, and 8a in Replication and Pathogenesis, mBio, doi:10.1128/mBio.02325-17
Cocchi, Chiale, Gianoglio, Deorsola, Napoleone et al., Colchicine: An Impressive Effect on Posttransplant Capillary Leak Syndrome and Renal Failure, Pediatrics, doi:10.1542/peds.2018-2820
Deftereos, Giannopoulos, Vrachatis, Siasos, Giotaki et al., Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial, JAMA Netw Open, doi:10.1001/jamanetworkopen.2020.13136
Della-Torre, Della-Torre, Kusanovic, Scotti, Ramirez et al., Treating COVID-19 with colchicine in community healthcare setting, Clin Immunol, doi:10.1016/j.clim.2020.108490
Dupuis, Sirois, Rhe ´aume, Nguyen, Brand, Colchicine reduces lung injury in experimental acute respiratory distress syndrome, PLoS One, doi:10.1371/journal.pone.0242318
Group, Horby, Lim, Emberson, Mafham et al., Dexamethasone in Hospitalized Patients with Covid-19-Preliminary Report, N Engl J Med, doi:10.1056/NEJMoa2021436
Imazio, Brucato, Cemin, Ferrua, Maggiolini et al., A randomized trial of colchicine for acute pericarditis, N Engl J Med, doi:10.1056/NEJMoa1208536
Karamanou, Tsoucalas, Pantos, Androutsos, Isolating Colchicine in 19th Century: An Old Drug Revisited, Curr Pharm Des, doi:10.2174/1381612824666180115105850
Martı ´nez, Robertson, Barraclough, Xia, Mallat et al., Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary Syndrome, J Am Heart Assoc, doi:10.1161/JAHA.115.002128
Mehta, Mcauley, Brown, Sanchez, Tattersall et al., COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet, doi:10.1016/S0140-6736(20)30628-0
Montealegre-Gomez, Garavito, Gomez-Lopez, Rojas-Villarraga, Parra-Medina, Colchicine: a potential therapeutic tool against COVID-19
Nidorf, Thompson, Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview, Clin Ther, doi:10.1016/j.clinthera.2018.11.016
Nieto-Torres, Verdia, ´guena, Jimenez-Guardeño, Regla-Nava et al., Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome, Virology, doi:10.1016/j.virol.2015.08.010
Nonaka, Takase, Machii, Ohno, Colchicine therapy for deep vein thrombosis in a patient with vascular-type Behc ¸et disease: A case report, Medicine, doi:10.1097/MD.0000000000019814
Qin, Zhou, Hu, Zhang, Yang et al., Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China, Clin Infect Dis, doi:10.1093/cid/ciaa248
Scarsi, Piantoni, Colombo, Airo, Richini et al., Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217712
{ 'indexed': {'date-parts': [[2022, 2, 3]], 'date-time': '2022-02-03T13:30:57Z', 'timestamp': 1643895057043}, 'reference-count': 18, 'publisher': 'Public Library of Science (PLoS)', 'issue': '3', 'license': [ { 'start': { 'date-parts': [[2021, 3, 24]], 'date-time': '2021-03-24T00:00:00Z', 'timestamp': 1616544000000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by/4.0/'}], 'funder': [{'name': 'NIH NIAID', 'award': ['3U01AI063594-17S1']}], 'content-domain': {'domain': ['www.plosone.org'], 'crossmark-restriction': False}, 'short-container-title': ['PLoS ONE'], 'abstract': '<jats:sec id="sec001">\n' '<jats:title>Objectives</jats:title>\n' '<jats:p>Effective treatments for coronavirus disease 2019 (COVID-19) are urgently needed. We ' 'hypothesized that colchicine, by counteracting proinflammatory pathways implicated in the ' 'uncontrolled inflammatory response of COVID-19 patients, reduces pulmonary complications, and ' 'improves survival.</jats:p>\n' '</jats:sec>\n' '<jats:sec id="sec002">\n' '<jats:title>Methods</jats:title>\n' '<jats:p>This retrospective study included 71 consecutive COVID-19 patients (hospitalized with ' 'pneumonia on CT scan or outpatients) who received colchicine and compared with 70 control ' 'patients who did not receive colchicine in two serial time periods at the same institution. ' 'We used inverse probability of treatment propensity-score weighting to examine differences in ' 'mortality, clinical improvement (using a 7-point ordinary scale), and inflammatory markers ' 'between the two groups.</jats:p>\n' '</jats:sec>\n' '<jats:sec id="sec003">\n' '<jats:title>Results</jats:title>\n' '<jats:p>Amongst the 141 COVID-19 patients (118 [83.7%] hospitalized), 70 (50%) received ' 'colchicine. The 21-day crude cumulative mortality was 7.5% in the colchicine group and 28.5% ' 'in the control group (P = 0.006; adjusted hazard ratio: 0.24 [95%CI: 0.09 to 0.67]); 21-day ' 'clinical improvement occurred in 40.0% of the patients on colchicine and in 26.6% of control ' 'patients (adjusted relative improvement rate: 1.80 [95%CI: 1.00 to 3.22]). The strong ' 'association between the use of colchicine and reduced mortality was further supported by the ' 'diverging linear trends of percent daily change in lymphocyte count (P = 0.018), ' 'neutrophil-to-lymphocyte ratio (P = 0.003), and in C-reactive protein levels (P = 0.009). ' 'Colchicine was stopped because of transient side effects (diarrhea or skin rashes) in 7% of ' 'patients.</jats:p>\n' '</jats:sec>\n' '<jats:sec id="sec004">\n' '<jats:title>Conclusion</jats:title>\n' '<jats:p>In this retrospective cohort study colchicine was associated with reduced mortality ' 'and accelerated recovery in COVID-19 patients. This support the rationale for current larger ' 'randomized controlled trials testing the safety/efficacy profile of colchicine in COVID-19 ' 'patients.</jats:p>\n' '</jats:sec>', 'DOI': '10.1371/journal.pone.0248276', 'type': 'journal-article', 'created': {'date-parts': [[2021, 3, 24]], 'date-time': '2021-03-24T17:33:25Z', 'timestamp': 1616607205000}, 'page': 'e0248276', 'update-policy': 'http://dx.doi.org/10.1371/journal.pone.corrections_policy', 'source': 'Crossref', 'is-referenced-by-count': 14, 'title': [ 'Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, ' 'observational study'], 'prefix': '10.1371', 'volume': '16', 'author': [ {'given': 'Lucio', 'family': 'Manenti', 'sequence': 'first', 'affiliation': []}, {'given': 'Umberto', 'family': 'Maggiore', 'sequence': 'additional', 'affiliation': []}, {'given': 'Enrico', 'family': 'Fiaccadori', 'sequence': 'additional', 'affiliation': []}, {'given': 'Tiziana', 'family': 'Meschi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Anna Degli', 'family': 'Antoni', 'sequence': 'additional', 'affiliation': []}, {'given': 'Antonio', 'family': 'Nouvenne', 'sequence': 'additional', 'affiliation': []}, {'given': 'Andrea', 'family': 'Ticinesi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nicoletta', 'family': 'Cerundolo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Beatrice', 'family': 'Prati', 'sequence': 'additional', 'affiliation': []}, {'given': 'Marco', 'family': 'Delsante', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ilaria', 'family': 'Gandoflini', 'sequence': 'additional', 'affiliation': []}, {'given': 'Lorenzo', 'family': 'Donghi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Micaela', 'family': 'Gentile', 'sequence': 'additional', 'affiliation': []}, {'given': 'Maria Teresa', 'family': 'Farina', 'sequence': 'additional', 'affiliation': []}, {'given': 'Vincenzo', 'family': 'Oliva', 'sequence': 'additional', 'affiliation': []}, {'given': 'Cristina', 'family': 'Zambrano', 'sequence': 'additional', 'affiliation': []}, {'given': 'Giuseppe', 'family': 'Regolisti', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alessandra', 'family': 'Palmisano', 'sequence': 'additional', 'affiliation': []}, {'given': 'Caterina', 'family': 'Caminiti', 'sequence': 'additional', 'affiliation': []}, {'given': 'Enrico', 'family': 'Cocchi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Carlo', 'family': 'Ferrari', 'sequence': 'additional', 'affiliation': []}, {'given': 'Leonardo V.', 'family': 'Riella', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-7837-0923', 'authenticated-orcid': True, 'given': 'Paolo', 'family': 'Cravedi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Licia', 'family': 'Peruzzi', 'sequence': 'additional', 'affiliation': []}], 'member': '340', 'published-online': {'date-parts': [[2021, 3, 24]]}, 'reference': [ { 'issue': '4', 'key': 'pone.0248276.ref001', 'doi-asserted-by': 'crossref', 'first-page': '644', 'DOI': '10.1016/j.jiph.2020.02.033', 'article-title': 'The outbreak of Coronavirus Disease 2019 (COVID-19)-An emerging global ' 'health threat', 'volume': '13', 'author': 'S Arshad Ali', 'year': '2020', 'journal-title': 'J Infect Public Health'}, { 'issue': '10229', 'key': 'pone.0248276.ref002', 'doi-asserted-by': 'crossref', 'first-page': '1033', 'DOI': '10.1016/S0140-6736(20)30628-0', 'article-title': 'COVID-19: consider cytokine storm syndromes and immunosuppression', 'volume': '395', 'author': 'P Mehta', 'year': '2020', 'journal-title': 'Lancet'}, { 'issue': '15', 'key': 'pone.0248276.ref003', 'doi-asserted-by': 'crossref', 'first-page': '762', 'DOI': '10.1093/cid/ciaa248', 'article-title': 'Dysregulation of Immune Response in Patients With Coronavirus 2019 ' '(COVID-19) in Wuhan, China', 'volume': '71', 'author': 'C Qin', 'year': '2020', 'journal-title': 'Clin Infect Dis'}, { 'key': 'pone.0248276.ref004', 'doi-asserted-by': 'crossref', 'first-page': '330', 'DOI': '10.1016/j.virol.2015.08.010', 'article-title': 'Severe acute respiratory syndrome coronavirus E protein transports ' 'calcium ions and activates the NLRP3 inflammasome', 'volume': '485', 'author': 'JL Nieto-Torres', 'year': '2015', 'journal-title': 'Virology'}, { 'issue': '3', 'key': 'pone.0248276.ref005', 'doi-asserted-by': 'crossref', 'first-page': 'e02325', 'DOI': '10.1128/mBio.02325-17', 'article-title': 'Role of Severe Acute Respiratory Syndrome Coronavirus Viroporins E, 3a, ' 'and 8a in Replication and Pathogenesis', 'volume': '9', 'author': 'C Castaño-Rodriguez', 'year': '2018', 'journal-title': 'mBio'}, { 'issue': '6', 'key': 'pone.0248276.ref006', 'doi-asserted-by': 'crossref', 'first-page': '654', 'DOI': '10.2174/1381612824666180115105850', 'article-title': 'Isolating Colchicine in 19th Century: An Old Drug Revisited', 'volume': '24', 'author': 'M Karamanou', 'year': '2018', 'journal-title': 'Curr Pharm Des'}, { 'issue': '16', 'key': 'pone.0248276.ref007', 'doi-asserted-by': 'crossref', 'first-page': '1522', 'DOI': '10.1056/NEJMoa1208536', 'article-title': 'A randomized trial of colchicine for acute pericarditis', 'volume': '369', 'author': 'M Imazio', 'year': '2013', 'journal-title': 'N Engl J Med'}, { 'issue': '1', 'key': 'pone.0248276.ref008', 'doi-asserted-by': 'crossref', 'first-page': '41', 'DOI': '10.1016/j.clinthera.2018.11.016', 'article-title': 'Why Colchicine Should Be Considered for Secondary Prevention of ' 'Atherosclerosis: An Overview', 'volume': '41', 'author': 'SM Nidorf', 'year': '2019', 'journal-title': 'Clin Ther'}, { 'issue': '8', 'key': 'pone.0248276.ref009', 'doi-asserted-by': 'crossref', 'first-page': 'e002128', 'DOI': '10.1161/JAHA.115.002128', 'article-title': 'Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory ' 'Cytokines in Patients With an Acute Coronary Syndrome', 'volume': '4', 'author': 'GJ Martínez', 'year': '2015', 'journal-title': 'J Am Heart Assoc'}, { 'issue': '5', 'key': 'pone.0248276.ref010', 'doi-asserted-by': 'crossref', 'first-page': 'e20182820', 'DOI': '10.1542/peds.2018-2820', 'article-title': 'Colchicine: An Impressive Effect on Posttransplant Capillary Leak ' 'Syndrome and Renal Failure', 'volume': '143', 'author': 'E Cocchi', 'year': '2019', 'journal-title': 'Pediatrics'}, { 'issue': '19', 'key': 'pone.0248276.ref011', 'doi-asserted-by': 'crossref', 'first-page': '1787', 'DOI': '10.1056/NEJMoa2001282', 'article-title': 'A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe ' 'Covid-19', 'volume': '382', 'author': 'B Cao', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'issue': '6', 'key': 'pone.0248276.ref012', 'doi-asserted-by': 'crossref', 'first-page': 'e2013136', 'DOI': '10.1001/jamanetworkopen.2020.13136', 'article-title': 'Effect of Colchicine vs Standard Care on Cardiac and Inflammatory ' 'Biomarkers and Clinical Outcomes in Patients Hospitalized With ' 'Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial', 'volume': '3', 'author': 'SG Deftereos', 'year': '2020', 'journal-title': 'JAMA Netw Open'}, { 'issue': '12', 'key': 'pone.0248276.ref013', 'doi-asserted-by': 'crossref', 'first-page': 'e0242318', 'DOI': '10.1371/journal.pone.0242318', 'article-title': 'Colchicine reduces lung injury in experimental acute respiratory ' 'distress syndrome', 'volume': '15', 'author': 'J Dupuis', 'year': '2020', 'journal-title': 'PLoS One'}, { 'issue': '16', 'key': 'pone.0248276.ref014', 'doi-asserted-by': 'crossref', 'first-page': 'e19814', 'DOI': '10.1097/MD.0000000000019814', 'article-title': 'Colchicine therapy for deep vein thrombosis in a patient with ' 'vascular-type Behçet disease: A case report', 'volume': '99', 'author': 'D Nonaka', 'year': '2020', 'journal-title': 'Medicine (Baltimore)'}, { 'issue': '10', 'key': 'pone.0248276.ref015', 'doi-asserted-by': 'crossref', 'first-page': '1286', 'DOI': '10.1136/annrheumdis-2020-217712', 'article-title': 'Association between treatment with colchicine and improved survival in ' 'a single-centre cohort of adult hospitalised patients with COVID-19 ' 'pneumonia and acute respiratory distress syndrome', 'volume': '79', 'author': 'M Scarsi', 'year': '2020', 'journal-title': 'Ann Rheum Dis'}, { 'key': 'pone.0248276.ref016', 'doi-asserted-by': 'crossref', 'first-page': '108490', 'DOI': '10.1016/j.clim.2020.108490', 'article-title': 'Treating COVID-19 with colchicine in community healthcare setting', 'volume': '217', 'author': 'E Della-Torre', 'year': '2020', 'journal-title': 'Clin Immunol'}, { 'key': 'pone.0248276.ref017', 'article-title': 'Colchicine: a potential therapeutic tool against COVID-19. Experience ' 'of 5 patients', 'author': 'G Montealegre-Gomez', 'year': '2020', 'journal-title': 'Reumatol Clin'}, { 'key': 'pone.0248276.ref018', 'article-title': 'Dexamethasone in Hospitalized Patients with Covid-19—Preliminary Report', 'author': 'RC Group', 'year': '2020', 'journal-title': 'N Engl J Med'}], 'container-title': ['PLOS ONE'], 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://dx.plos.org/10.1371/journal.pone.0248276', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 3, 24]], 'date-time': '2021-03-24T17:33:53Z', 'timestamp': 1616607233000}, 'score': 1, 'subtitle': [], 'editor': [{'given': 'Antonio', 'family': 'Cannatà', 'sequence': 'first', 'affiliation': []}], 'short-title': [], 'issued': {'date-parts': [[2021, 3, 24]]}, 'references-count': 18, 'journal-issue': {'issue': '3', 'published-online': {'date-parts': [[2021, 3, 24]]}}, 'URL': 'http://dx.doi.org/10.1371/journal.pone.0248276', 'relation': {}, 'ISSN': ['1932-6203'], 'issn-type': [{'value': '1932-6203', 'type': 'electronic'}], 'subject': ['Multidisciplinary'], 'published': {'date-parts': [[2021, 3, 24]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit